Checkpoint Inhibitors Market

Global Checkpoint Inhibitors Market Size (2022 to 2027)

The global checkpoint inhibitors market is estimated to grow at a CAGR of 28.68% during the forecast period. The market's size is predicted to be USD 58.57 billion by 2027 from USD 16.60 billion in 2022.

Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead to an immune system attack on cancer cells. T-cells launch an attack when it detects infected or Cancerous. The immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells, which lets T-Cells launch an attack on cancer cells.

The rising Prevalence of cancer globally and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the Checkpoint Inhibitors Market.

Other prominent factors that drive the growth of the global checkpoint inhibitors market are increased funds, government support in developing new drugs, and the frequent rise in cancer. Precision in medicine will be a significant driver for pharmaceuticals to deliver innovative medicines. There is extreme competition in checkpoint inhibitors, driving learning or developing skills, and in-license agreements. Research developments also drive by learning institutes and industry contributors. By affecting the nation's cost, there is a need to address the day-to-day increase in cancer prevalence.

A comprehensive analysis of regions is to provide current opportunities. It also offers a quantitative study to enable the stakeholders to make a massive amount in market opportunities.

The high cost involved in research and development is one of the major factors restraining the global checkpoint inhibitors market. Also, the lack of awareness and proper publicity for using these inhibitors, especially in developing regions, are deterrents to expanding the global checkpoint inhibitors market.

REPORT COVERAGE:

This research report on the global checkpoint inhibitors market has been segmented and sub-segmented based on the drug, application, and region.

Checkpoint Inhibitors Market - By Drug:

• PD-1 inhibitors
• PD-L1 inhibitors
• CTLA-4
• Chimeric Antigen Receptor T-cell
• Others

The CTLA-4 segment holds the highest share based on drugs, accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market shares to the PD-1 inhibitors segment during the forecast period, as most new treatments are based on PD-1 inhibitors.

Checkpoint Inhibitors Market - By Application:

• Lung Cancer
• Renal Cancer
• Blood Cancer
• Bladder Cancer
• Hodgkin Lymphoma
• Melanoma
• Others

Checkpoint Inhibitors Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Geographically, North America dominates the global checkpoint inhibitors market, owing to the high number of clinics and the available funds. But, APAC, i.e., Asia-Pacific, is the fastest-growing region. In this region, international players collaborate with local companies. As a result, Asia-Pacific produces a great deal of profit for the key players operating in the immune checkpoint inhibitors market, which is supported by its large population and their awareness of immune therapy, etc. 

Latin America and, the Middle East & Africa are also expected to produce a great deal of profit for the key players during the forecast period. Furthermore, due to healthcare development, there will be a rise in demand for the checkpoint inhibitors market in all parts of the world.

KEY MARKET PLAYERS:

Notable companies leading the global checkpoint inhibitors market covered in this report are Merck & Co. Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd, Juno Therapeutics, Novartis International AG, and Kite Pharma.

RECENT MARKET HAPPENINGS:

• In February 2019, Merck & Co., Inc. announced that they had received US FDA approval for the checkpoint inhibitor “Keytruda,” which is used to treat Merkel cell carcinoma.
• For the treatment of non-small cell lung cancer in advanced stages, F. Hoffmann-La Roche Ltd. announced in January 2019 that they received US FDA approval for “Tecentriq, in combination with bevacizumab, paclitaxel, and carboplatin.
• In October 2018, for the treatment of advanced cutaneous squamous cell carcinoma, Regeneron announced that they had received US FDA approval for “Libtayo.”